JLJ M Luccarini

J M Luccarini

*This is an algorithmically generated author record based on publicly available information.

J M Luccarini has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis

    by G. Wettstein, L. Poekes, F. Oakley, P. Faye, J.-M. Luccarini, P. Broqua, J.-L. Junien, D. Mann, I. Leclercq, I. Konstantinova


  • The New Generation Pan-Ppar Agonist Iva337 Protects the Liver from Metabolic Disorders and Fibrosis

    by G. Wettstein, C. Estivalet, J. Tessier, P.T. Boustugue, I. Jantzen, E. Defrene, F. Kupkowski, P. Faye, V. Adarbes, J.-M. Germain, et al.


  • Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats

    by P Belichard, J M Luccarini, E Defrêne, P Faye, R M Franck, H Duclos, J L Paquet, D Pruneau

    In the present study, we developed an experimental model of cystitis induced by cyclophosphamide (CYP). In order to characterize des‐Arg9‐BK‐induced contraction on the urinary bladder (UB) during the development of inflammation and to quantify kinin B1 receptor gene expression using a quantitative RT–PCR technique. In the presence of peptidase inhibitors captopril (10 μM), DL‐thiorphan (1 μM) and DL‐2‐mercaptomethyl‐3‐guanidino‐ethylthiopropanoic acid (MERGEPTA 5 μM), bradykinin (BK) (0.3–3,000 nM) evoked a concentration‐dependent contraction of rat UB which was not different between the CYP‐ and vehicle‐treated groups. Unlike BK, des‐Arg9‐BK (0.3–100,000 nM) did not contract UB from vehicle‐treated rats but contracted vigorously bladder strips from CYP‐treated rats 14, 24 and 168 h after treatment. In UB of 24 h treated rat, the pD2 value of des‐Arg9‐BK was 7.3±0.1. The cyclo‐oxygenase inhibitor indomethacin (3 μM) reduced by 30% the maximal response of des‐Arg9‐BK. Both the kinin B1 receptor antagonists des‐Arg9‐[Leu8]BK (10 μM) and des‐Arg10‐Hoe 140 (10 μM) produced a rightward shift of the concentration‐response curve to des‐Arg9‐BK yielding pKB values of 6.8±0.2 and 7.2±0.1, respectively, whilst the kinin B2 receptor antagonist Hoe 140 (1 μM) had no effect. After CYP treatment, mRNA coding for the kinin B1 receptor appeared predominantly in UB. In this organ, the induction was progressive, reaching a maximum 48 h after CYP treatment. In conclusion, the present study provides strong evidence for an induction of kinin B1 receptors in UB of CYP‐treated rats. This was associated at a molecular level with an increase in mRNA expression of the gene coding for the kinin B1 receptor. This kinin receptor displayed the whole features of a classical rat kinin B1 receptor. British Journal of Pharmacology (1999) 128, 213–219; doi:10.1038/sj.bjp.0702769


  • Open Access

    The kinin B1 receptor antagonist des‐Arg9‐[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor

    by D. Pruneau, A. Duvoid, J.M. Luccarini, P. Bélichard, J.C. Bonnafous

    1 Agonists and antagonists of kinin B1 and B2 receptors were evaluated in vitro for their effects against angiotensin II (AII)-induced contractile responses in the rabbit aorta and for their binding properties to angiotensin AT1 and AT2 receptors from purified membrane of rat liver and lamb uterus respectively. 2 In aortic rings, the kinin B1 receptor antagonist, des-Arg9-[Leu8]bradykinin (BK) (3–100 μm) caused a concentration-dependent decrease in sensitivity and a depression of the maximum response to AII. Des-Arg10-[Leu9]kallidin (KD), des-Arg9-BK, des-Arg10-KD, BK or KD at 3 μm had no effect against All-induced contractions. 3 Des-Arg9-[Leu8]BK (3 or 100 μm) did not affect contractions of aortic rings to histamine, potassium chloride, endothelin-1, 5-hydroxytryptamine, noradrenaline and the thromboxane A2-mimetic, U46619. 4 Des-Arg9-[Leu8]BK displaced [125I]-Sar1-AII binding to the AT1 subtype in rat liver membranes with a Ki value of 1.1 ± 0.4 μm. Values of Ki for des-Arg9-BK and KD were 45 ± 13 μm and 25 ± 22 μm, respectively. The other kinin derivatives des-Arg10-KD, BK and des-Arg10-[Leu9]KD at concentrations up to 100 μm did not bind to the AT1 receptor. 5 All the kinin derivatives except BK bound to AT2 receptors in lamb uterus membranes. Values of Ki for des-Arg9-[Leu8]BK, des-Arg10-[Leu9]KD, des-Arg9-BK, des-Arg10-KD and KD were 0.3 ± 0.1, 0.7 ± 0.1, 1.2 ± 0.3, 1.5 ± 0.3 and 7.0 ± 1.6 μm, respectively. 6 In conclusion, des-Arg9-[Leu8]BK is an insurmountable antagonist of All-induced contractions in the rabbit aorta and also binds with a relatively high affinity to AT1 and AT2 receptors in isolated membrane fractions. These additional properties of des-Arg9-[Leu8]BK should be considered when it is used as an antagonist to characterize kinin B1 receptors.